Cargando…

Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital

PURPOSE: To describe the tolerability and efficacy of neratinib as a monotherapy and in combination with capecitabine in advanced HER2-positive breast cancer in a real-world setting. METHODS: Patients who received neratinib for advanced HER2-positive at the Royal Marsden Hospital NHS Trust between A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cunningham, Niamh, Shepherd, Scott, Mohammed, Kabir, Lee, Karla A., Allen, Mark, Johnston, Stephen, Kipps, Emma, McGrath, Sophie, Noble, Jillian, Parton, Marina, Ring, Alistair, Turner, Nicholas C., Okines, Alicia F. C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382612/ https://www.ncbi.nlm.nih.gov/pubmed/35976513 http://dx.doi.org/10.1007/s10549-022-06703-3

Ejemplares similares

Trastuzumab beyond progression in HER2-positive advanced breast cancer: The Royal Marsden experience
por: Waddell, T, et al.
Publicado: (2011)

Treatment of Epithelioid Sarcoma at the Royal Marsden Hospital
por: Livi, L., et al.
Publicado: (2003)

Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital.
por: Swerdlow, A. J., et al.
Publicado: (1997)

Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens
por: Moy, Beverly, et al.
Publicado: (2021)

Ovarian metastases from primary gastrointestinal malignancies: the Royal Marsden Hospital experience and implications for adjuvant treatment.
por: Taylor, A. E., et al.
Publicado: (1995)

The Royal Marsden experience of a small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil.
por: Crawley, C., et al.
Publicado: (1998)

Dr. Marsden
Publicado: (1836)

Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): The Royal Marsden Hospital (RMH) experience
por: Khan, Khurum, et al.
Publicado: (2015)

Pazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience
por: Maruzzo, Marco, et al.
Publicado: (2015)

Adjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study.
por: Bamias, A., et al.
Publicado: (1995)

Dr. Marsden’s Plan of Quarantine
Publicado: (1866)

Neratinib for HER2-positive breast cancer with an overlooked option
por: Guo, Liting, et al.
Publicado: (2023)

Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens
por: Dai, Ming Shen, et al.
Publicado: (2021)

De-escalation of adjuvant chemotherapy for HER2 negative breast cancer
por: Okines, Dr Alicia FC, et al.
Publicado: (2021)

Transcriptome analysis of neratinib treated HER2 positive cancer model vs untreated cancer unravels the molecular mechanism of action of neratinib
por: Alkhezayem, Sara, et al.
Publicado: (2020)

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2013)

Neratinib for the Treatment of Early-Stage HER2-Positive Breast Cancer
por: Miles, Jennifer, et al.
Publicado: (2018)

Neratinib for Extended Anti-HER2 Therapy in Early Breast Cancer
por: Budd, G. Thomas, et al.
Publicado: (2018)

Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancer
por: Eli, Lisa D., et al.
Publicado: (2022)

Hormonal treatments in metastatic endometrial stromal sarcomas: the 10-year experience of the sarcoma unit of Royal Marsden Hospital
por: Thanopoulou, Eirini, et al.
Publicado: (2015)

The practical aspects of propofol target controlled infusion for magnetic resonance imaging in children: An audit from the Royal Marsden Hospital
por: Haberman, Emily, et al.
Publicado: (2013)

Geometry, mechanics, and dynamics: the legacy of Jerry Marsden
por: Chang, Dong, et al.
Publicado: (2015)

The stretch reflex and the contributions of C David Marsden
por: Bhattacharyya, Kalyan B.
Publicado: (2017)

Neratinib for breast cancer
Publicado: (2019)

Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience
por: Arkenau, H-T, et al.
Publicado: (2008)

Reply: Clinical outcome and prognostic factors for patients treated within a phase I study: the Royal Marsden Hospital Experience
por: Olmos, D, et al.
Publicado: (2008)

Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience
por: Tirelli, U
Publicado: (2008)

Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib
por: Kourie, Hampig Raphael, et al.
Publicado: (2017)

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
por: Harding, James J., et al.
Publicado: (2023)

Student’s guide to calculus by J. Marsden and A. Weinstein
por: Soon, Frederick H
Publicado: (1985)

John Marsden's will: the Hornby estate case 1780–1840
por: Watson, Katherine D
Publicado: (2000)

BRCA1, BRCA2 and pedigree genetic analysis to determine genetic risk in the UK Royal Marsden Hospital tamoxifen prevention trial
por: Kote-Jarai, Z, et al.
Publicado: (2000)

Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Prognostic Markers for Extensive Disease of Small Cell Lung Cancer
por: Minami, Seigo, et al.
Publicado: (2020)

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
por: Saura, Cristina, et al.
Publicado: (2021)

How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer
por: Untch, Michael, et al.
Publicado: (2021)

Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer
por: Richman, Juliet, et al.
Publicado: (2020)

Melatonin potentiates the cytotoxic effect of Neratinib in HER2(+) breast cancer through promoting endocytosis and lysosomal degradation of HER2
por: Liu, Zundong, et al.
Publicado: (2021)

97P Is continuing CDK4-6 inhibitor therapy safe during the COVID-19 pandemic? A UK cancer centre experience
por: Angelis, V., et al.
Publicado: (2021)

Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung Cancer
por: Minami, Seigo, et al.
Publicado: (2019)

Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer
por: Chow, L W-C, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_2rn7s6vi1t5u77agbgpq3vrokv